Last updated: July 28, 2026
Litigation summary and analysis: Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., 2:23-cv-00511 (ANDA/Dayvigo)
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., No. 2:23-cv-00511 (filed 2023), is a patent infringement dispute tied to Teva’s Abbreviated New Drug Application (ANDA) entry planning for Dayvigo (lemborexant). The case centers on whether Teva’s proposed generic product infringes one or more Orange-Book-listed Vanda patents and whether any challenges under the Hatch-Waxman framework are legally valid.
What patent(s) are asserted in Vanda v. Teva, 2:23-cv-00511?
The case caption alone does not identify the asserted patents or their numbers. Without the complaint, infringement contentions, or docket entries specifying the asserted claims, a litigation-grade analysis (including claim scope, expiration, and validity/unenforceability arguments) cannot be produced accurately.
Core litigation components typically determined in this forum (but not identifiable from the docket number alone)
- Which Vanda patents are asserted (composition, formulation, method-of-use, or manufacturing)
- Which specific claims are alleged infringed
- Teva’s defenses
- Invalidity (anticipation/obviousness/indefiniteness/written description)
- Non-infringement (non-matching limitations)
- Unenforceability (inequitable conduct, prosecution history issues)
- Hatch-Waxman timing relief sought
- Infringement injunction contingent on “successful” Paragraph IV findings
- Remedies post-authorization
What is the procedural posture in 2:23-cv-00511 and what motions matter?
A docket-only reference (case number and party names) does not provide the procedural posture. A litigation summary that is useful for investment, licensing, or litigation strategy must report:
- complaint filing date and asserted patents
- Teva’s answer (denials and affirmative defenses)
- any Rule 12 motions (dismissal), claim construction schedule, summary judgment posture
- Markman/claim construction orders and their holdings
- trial dates or settlement indicators
No procedural filings are included in the prompt. Without that, a complete and accurate procedural narrative cannot be generated.
What patents protect Dayvigo (lemborexant) and how does this case likely map to them?
A reliable mapping requires identifying the exact Orange-Book patents asserted in this specific case. Dayvigo has multiple potential IP layers across jurisdictions (small-molecule composition, polymorph/formulation, and method-of-use). But attributing any particular patent family to this case without docket-level confirmation would be speculative.
Typical Dayvigo patent categories seen in ANDA litigation
- Drug substance composition and/or crystalline forms
- Drug product formulation (e.g., solid-state, excipient systems, film/tablet parameters)
- Method-of-use or dosing regimens (e.g., insomnia endpoints, administration timing)
- Manufacturing method claims (less common than composition/formulation but possible)
Who filed the ANDA, what is the Paragraph IV posture, and when does exclusivity end?
A litigation-grade Paragraph IV analysis requires:
- Teva’s ANDA number
- the listed Orange-Book patents against which Teva submitted certifications
- whether Teva filed “Paragraph IV” certifications as to specific patents
- the “falsified” or “invalid” arguments actually pleaded
- any forfeiture or 30-month stay events tied to FDA acceptance/approval timing
The prompt provides none of those identifiers, so a correct exclusivity timeline or entry-risk assessment cannot be produced.
What does the litigation say about Teva’s generic entry risks?
Entry-risk modeling depends on litigation outcomes tied to specific patents:
- injunction risk if asserted claims are found infringed and patents survive
- design-around feasibility if non-infringement appears likely after claim construction
- settlement plausibility if both sides signal narrowing claim sets or consent judgments
Those determinations require the actual order record and claim-level rulings, which are not provided.
How strong is Vanda’s patent estate in this case?
Strength must be derived from:
- asserted claim elements
- prior art used in obviousness/anticipation arguments
- prosecution history constraints and whether validity attacks target the same limitations
- any judicial claim construction narrowing that favors the branded product
Without asserted patent numbers and court rulings, a defensible “strength” assessment is not possible.
What is the comparative litigation landscape: Vanda vs. other ANDA filers?
A business-useful landscape requires:
- whether other companies are litigating the same Orange-Book patents for Dayvigo
- whether there are settlements that establish market entry dates or license terms
- whether courts have already construed key claim terms in the same patent family
None of this can be grounded to No. 2:23-cv-00511 without docket and related-case data.
What are the settlement signals, if any, in 2:23-cv-00511?
Settlement analysis must reference docket events such as:
- stipulations of dismissal with prejudice
- consent judgments
- orders sealing settlement
- jointly filed claim dismissal or modified contentions
No docket events are supplied in the prompt, so settlement status cannot be stated accurately.
What is the FDA/regulatory status impact from this litigation?
Patent cases can affect FDA timelines through:
- 30-month stay triggers
- whether the FDA approval is stayed pending litigation outcomes
- whether a “carve-out” design permits launch notwithstanding an injunction
Those impacts depend on ANDA submission facts and court orders. No FDA linkage details are provided.
Key Takeaways
- The case identification provided (Vanda v. Teva, 2:23-cv-00511) is insufficient to produce a complete litigation summary with asserted patents, claim-level allegations, procedural posture, rulings, and entry-risk implications.
- A litigation-grade analysis requires docket-specific facts (complaint, asserted patent list, claim construction, dispositive motions, and any settlement orders). Those are not contained in the prompt.
FAQs
1) What patents does Vanda assert against Teva in 2:23-cv-00511?
Not provided in the prompt, so the asserted patent list cannot be stated.
2) Is this case a Paragraph IV ANDA challenge?
The prompt does not state the ANDA number or certification type.
3) What court decisions occurred in 2:23-cv-00511?
No docket events or orders are included in the prompt.
4) When can Teva’s generic Dayvigo be launched if it wins?
A launch timeline depends on patent expiration and any injunctions, which require asserted-patent and ruling details.
5) Did Vanda reach a settlement with Teva?
Settlement signals require docket confirmation (dismissal/consent judgments), not available here.
References
- Federal case docket information (case number and caption only): Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., No. 2:23-cv-00511 (U.S. District Court).
